Skip to main content

Advertisement

SpringerLink
Log in

Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

The risk of secondary events following noncardioembolic ischemic stroke or transient ischemic attack (TIA) is high and especially pronounced in the first days and weeks following the initial event; to reduce this risk, it is recommended that antiplatelet therapy be initiated immediately. Although the risk and impact of antiplatelet-associated side effects are generally far less substantial than those of secondary events, some (especially bleeding) can be severe and even life-threatening, and others may reduce adherence to antiplatelet regimens. Therefore, clinicians should implement strategies to reduce the risk of side effects and to manage those that occur. Three antiplatelet regimens have demonstrated substantial reductions in secondary event risk and are currently recommended by consensus panels: aspirin monotherapy at 50–325 mg/day; the combination of aspirin plus extended-release dipyridamole (ER-DP); and clopidogrel monotherapy. Bleeding is potentially the most significant antiplatelet-associated side effect. As bleeding risk with aspirin monotherapy is dose dependent, while preventive efficacy appears similar at all doses above 50 mg/day, aspirin doses should be kept as low as possible. Clopidogrel bleeding risk is similar to aspirin, although a reduced incidence of gastrointestinal bleeding events suggests lower gastrotoxicity. Clopidogrel should not be combined with aspirin after stroke or TIA, as the combination increases bleeding risk without improving antiplatelet efficacy. Patients should be assessed for bleeding risk (especially gastrointestinal bleeding) before initiating antiplatelet therapy; those at elevated risk should be made aware of the signs and symptoms of bleeding events to facilitate prompt treatment. The addition of ER-DP to aspirin does not increase bleeding risk, although ER-DP is associated with risk of headache, which may be severe. The prevalence of headache drops rapidly following initiation of ER-DP, suggesting most patients are able to “push through” this side effect; for those who find headache intolerable, short-term use of a reduced-dose regimen may be helpful.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics — 2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–e215.

    Article  PubMed  Google Scholar 

  2. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:227–276.

    Article  PubMed  Google Scholar 

  3. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40:2276–2293.

    Article  PubMed  Google Scholar 

  4. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology. 2005;64:817–820.

    PubMed  Google Scholar 

  5. Johnston SC, Nguyen-Huynh MN, Schwarz ME, et al. National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol. 2006;60:301–313.

    Article  PubMed  Google Scholar 

  6. Coull AJ, Rothwell PM. Underestimation of the early risk of recurrent stroke: evidence of the need for a standard definition. Stroke. 2004;35:1925–1929.

    Article  PubMed  Google Scholar 

  7. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284:2901–2906.

    Article  PubMed  CAS  Google Scholar 

  8. Lovett JK, Dennis MS, Sandercock PA, Bamford J, Warlow CP, Rothwell PM. Very early risk of stroke after a first transient ischemic attack. Stroke. 2003;34:e138–140.

    Article  PubMed  CAS  Google Scholar 

  9. Fonarow GC, Smith EE, Reeves MJ, et al. Hospital-level variation in mortality and rehospitalization for Medicare beneficiaries with acute ischemic stroke. Stroke. 2011;42:159–166.

    Article  PubMed  Google Scholar 

  10. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(Suppl. 6):630S–669S.

    Article  PubMed  CAS  Google Scholar 

  11. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1–13.

    Article  PubMed  CAS  Google Scholar 

  12. [No authors listed.] A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med. 1991;325:1261–1266.

    Article  Google Scholar 

  13. [No authors listed.] Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet. 1991;338:1345–1349.

    Article  Google Scholar 

  14. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044–1054.

    Article  PubMed  CAS  Google Scholar 

  15. [No authors listed.] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–1339.

    Article  Google Scholar 

  16. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331–337.

    Article  PubMed  CAS  Google Scholar 

  17. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717.

    Article  PubMed  CAS  Google Scholar 

  18. The ESPIRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPIRIT): a randomised controlled trial. Lancet. 2006;367:1665–1673.

    Article  Google Scholar 

  19. Aggrenox (aspirin/extended-release dipyridamole) capsules. Prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2009.

    Google Scholar 

  20. Plavix (clopidogrel bisulfate). Prescribing information. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2010.

    Google Scholar 

  21. Derendorf H, VanderMaelen CP, Brickl RS, MacGregor TR, Eisert W. Dipyridamole bioavailability in subjects with reduced gastric acidity. J Clin Pharmacol. 2005;45:845–850.

    Article  PubMed  CAS  Google Scholar 

  22. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238–1251.

    Article  PubMed  CAS  Google Scholar 

  23. Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention — cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation — review and meta-analysis. J Intern Med. 2005;257:399–414.

    Article  PubMed  CAS  Google Scholar 

  24. Rahman M, Beattie J. Peri-operative medication in patients with cardiovascular disease. Pharm J. 2004;272:352–354.

    Google Scholar 

  25. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133(Suppl. 6):299S–339S.

    Article  PubMed  CAS  Google Scholar 

  26. Patrano, Carlo, Baigent C, Hirsh, Roth G. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2008;133(Suppl. 6):199S–233S.

    Article  Google Scholar 

  27. Theis JG, Deichsel G, Marshall S. Rapid development of tolerance to dipyridamole-associated headaches. Br J Clin Pharmacol. 1999;48:750–755.

    Article  PubMed  CAS  Google Scholar 

  28. Chang YJ, Ryu SJ, Lee TH. Dose titration to reduce dipyridamole-related headache. Cerebrovasc Dis. 2006;22:258–262.

    Article  PubMed  CAS  Google Scholar 

  29. Bennett CJ, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342:1773–1777.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ohio State University, 1380 Edgehill Road, Columbus, OH, 43212, USA

    Robert Guthrie

Authors
  1. Robert Guthrie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Guthrie.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guthrie, R. Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. Adv Therapy 28, 473–482 (2011). https://doi.org/10.1007/s12325-011-0026-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-011-0026-0

Keywords

Search

Navigation